JVM Co

JVM Co Financing Cash Flow

The Net Financing Cash Flow of JVM Co (054950.KQ) as of Nov 4, 2026 is -6.89 B KRW. In the previous year, Net Financing Cash Flow was -5.61 B KRW — a change of 22.86% (lower).

Financing Cash Flow

-6.89 BKRW

YoY

22.86%

Last updated:

Net Financing Cash Flow of JVM Co is 2024 -6.89 B KRW. Net Financing Cash Flow of JVM Co was 2023 -5.61 B KRW. It decreases by 22.86% lower compared to the previous year.

The JVM Co Financing Cash Flow history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financing Cash Flow
Date
Financing Cash Flow
Jan 1, 2017
-16.89 B KRW
Jan 1, 2018
-7.69 B KRW
Jan 1, 2019
-9.67 B KRW
Jan 1, 2020
2.70 B KRW
Jan 1, 2021
-4.36 B KRW
Jan 1, 2022
4.05 B KRW
Jan 1, 2023
-5.61 B KRW
Jan 1, 2024
-6.89 B KRW
The JVM Co Financing Cash Flow history
YEARFinancing Cash FlowYoY
-6.89 BKRW+22.86%
-5.61 BKRW-238.25%
4.05 BKRW-192.95%
-4.36 BKRW-261.86%
2.70 BKRW-127.87%
-9.67 BKRW+25.71%
-7.69 BKRW-54.45%
-16.89 BKRW-1,533.08%
1.18 BKRW-106.39%
-18.43 BKRW+44.70%
-12.74 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

JVM Co Stock analysis

What does JVM Co do? JVM Co., Ltd. manufactures pharmacy automation systems under the brand JVM, targeting domestic and overseas markets. The company's primary products include automatic tablet dispensing and packaging systems (ATDPSs), automatic tablet classification and packing machines available in slide, box, and drum types, total safety solutions, automatic medication vision inspection systems (VIZENs), automatic package cutting and winding systems (WIZERs), and automatic medication sorting and control systems (AccuPharm). These products are sold to customers in the pharmaceutical and healthcare sectors seeking efficient automation solutions for medication handling and safety. The firm generates revenue through the sale of its branded automation systems, with a focus on domestic distribution and international markets. JVM's product portfolio addresses key operational needs in pharmacy settings, including dispensing, classification, inspection, and sorting of medications, ensuring compliance with safety standards while improving workflow efficiency. The company's offerings are designed to meet the demands of healthcare providers and pharmaceutical manufacturers requiring advanced automation technologies. JVM's business model centers on providing comprehensive automation solutions for pharmacy operations, leveraging its established brand JVM to differentiate its products in the market. By offering a wide range of specialized systems, the company caters to both domestic and international clients seeking reliable, high-quality automation equipment for medication management and safety protocols. JVM Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about JVM Co stock

Net Financing Cash Flow of JVM Co is -6.89 B KRW in 2024.

Net Financing Cash Flow of JVM Co changed from -5.61 B KRW to -6.89 B KRW, representing a 22.86% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Financing Cash Flow JVM Co since 2006 – with annual values, charts, and detailed analysis.

Financing cash flow measures cash flows from debt issuance/repayment, equity transactions, and dividend payments.

Net Financing Cash Flow's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Financing Cash Flow's JVM Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — JVM Co

All Key Metrics — JVM Co